Iovance Biotherapeutics reported early pilot trial results for lifileucel in aggressive soft tissue sarcomas. The company plans to start a registrational trial and seek expedited FDA approval based on ...

A cohort of 253 isolated LR resections from 3211 primary STS resections enabled evaluation of post-recurrence prognosticators with median 5.3-year follow-up and 83 disease-specific deaths. Higher LR ...

A systematic review finds that diagnostic discordance in bone and soft tissue sarcoma may reduce survival, supporting expert second opinions. STS is a rare cancer that originates as an abnormal growth ...

Synovial sarcoma, a rare cancer, thrives on glutamine. Blocking its nutrient supply with the drug V9302 stops tumor growth, offering a new way to treat the disease.

Hidden within cancer DNA data, researchers uncovered viruses and bacteria that may influence both diagnosis and survival.

Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ... Read More The post Health Check: Telix jumps first hurdle with its ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, /CNW/ — Equity-Insider.com News Commentary — The five-year cancer survival rate in the United States has reached a record 70% ...

PARIS, FRANCE, 09 March 2026 ? Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen's decision ...

Shifting the focus from organ to biomarker has unlocked new options for rare and advanced cancers. Uneven efficacy, diagnostic access, and regulation still slow clinical rollout.

Pazopanib produced responses and acceptable safety in paclitaxel-pretreated angiosarcoma; read more about outcomes and ...

AS India witnesses a steady rise in cancer cases, with projections indicating a sharp increase in lung, breast, prostate and gastrointestinal cancers in the com ...